BMEA

#3843
Biomea Fusion, Inc. - Common Stock
1.7 3 USD
+0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.73
1.73
Jahresspanne
0.87
2.99
Tagesänderung
+2.98%
Monatliche Änderung
+42.98%
6 month change
+26.28%
Jahresänderung
-11.73%
Vorheriger Schlusskurs
1.6 8
Open
1.7 3
Tief
1.7 3
Hoch
1.7 3
Volumen
27
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Biomea Fusion, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Biomea Fusion, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Biomea Fusion, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Biomea Fusion, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Biomea Fusion, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Biomea Fusion, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Biomea Fusion, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Biomea Fusion, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Biomea Fusion, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Biomea Fusion, Inc. annual report, FY2025
10-K

Biomea Fusion, Inc. current report, Q1 FY2026

Full document

Biomea Fusion, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Biomea Fusion, Inc. (Nasdaq: BMEA) on January 14, 2026. The filing discloses events related to the company's participation in the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco from January 12-15, 2026.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosures regarding investor presentations rather than financial performance data.

Material Changes

No material changes to financial results or operations are reported in this document. The primary events are:

  • Item 7.01: Disclosure of a presentation delivered at the J.P. Morgan Healthcare Conference.
  • Item 8.01: Update to the company's corporate presentation used for investor and analyst communications.

Guidance, Outlook, and Risks

The filing includes a standard "Forward-Looking Statements" section. Management commentary and future projections are contained within the attached exhibits (Exhibit 99.1 and 99.2) rather than the body of the 8-K. Key risks and uncertainties highlighted include:

  • Potential delays in preclinical or clinical development and patient enrollment.
  • The risk that preliminary or interim study results may not predict future outcomes.
  • Uncertainties regarding regulatory plans and engagement with the U.S. Food and Drug Administration.
  • The company disclaims any obligation to update forward-looking statements except as required by law.

Investor Verification Checklist

  • Review Exhibit 99.1 for the specific content of the J.P. Morgan Healthcare Conference presentation.
  • Review Exhibit 99.2 for the updated corporate presentation and any new strategic guidance.
  • Verify the company's current cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K does not contain financial data.
  • Monitor upcoming clinical trial data readouts mentioned in the exhibits for potential impact on stock valuation.

Nachrichten